Abhisek Swaika, MD to Lead Northwell Cancer Institute at Rego Park

Northwell Health has appointed Abhisek Swaika, MD, as medical director of the Northwell Health Cancer Institute at Rego Park and chief of hematology/oncology at Long Island Jewish Forest Hills Hospital.

Northwell Health Cancer Institute at Rego Park, formerly Queens Medical Associates, is known for its culturally sensitive, state-of-the-art care and is committed to working with patients in their own languages. It’s cancer specialists and staff speak more than 30 languages and dialects. Dr. Swaika’s fluency in Hindi and Bengali exemplifies the practice’s diverse, patient-centered care.

“Dr. Abhisek Swaika is deeply committed to ensuring the delivery of the highest quality, state-of-the art cancer care,” said Richard Carvajal, MD, deputy physician-in-chief and director of medical oncology at Northwell Health Cancer Institute. “His leadership and experience will continue to drive our mission to care for the diverse patient population we have the privilege to see at our cancer center in Queens.”

Prior to joining Northwell, Dr. Abhisek  Swaika worked for three years at Queens Medical Associates, which integrated with Northwell in 2020. He is board-certified in internal medicine, hematology and medical oncology.

“I’m excited to be part of an extraordinary team committed to providing comprehensive cancer care in the heart of the Queen’s community,” said Dr. Swaika. “My vision is to further expand accessibility and participation of our patients in our growing clinical trial research program.”

Dr. Swaika earned his medical degree from Kasturba Medical College in India. He completed his residency at the State University of New York at Buffalo, followed by a fellowship at Mayo Clinic in Jacksonville, where he remained as an attending physician until 2017.

His research has been published in several journals, including Blood, American Journal of Hematology and Annals of Hematology. Dr. Swaika was nominated in 2023 for the Truly Award, a recognition of physicians by Northwell who go above and beyond to raise the standard of health care. He is actively involved in the Lead NEXT Development Program, which supports emerging leaders across the health care system. Additionally, Dr. Swaika serves on the Protocol Review and Monitoring Committee of the Northwell Health Cancer Institute.

Northwell, which cares for more New Yorkers with cancer than anyone else, is dedicated to providing the highest quality and safest medical care for optimal outcomes. In his new positions as medical director and chief of hematology/oncology, Dr. Swaika will continue his commitment to exceptional leadership at Northwell Cancer Institute at Rego Park and advance Northwell’s medical oncology and hematology services at LIJ Forest Hills.

For more information or to book an appointment, go to: https://www.northwell.edu/find-care/find-a-doctor/dr-abhisek-swaika-md-11379294.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”